KDR and melanoma: In both T cells and YT NK cells, anti-VEGFR2 CAR transduction with an alternative design- replacing the scFv domain conventionally derived from monoclonal antibodies with an analogous fibronectin type III (Fn3) domain- successfully produced cytotoxicity against melanoma cells [201].